← All stories
Markets
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
An experimental Novartis drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study
Covered by 1 outlet
All coverage · 1 article